Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
CompletedOBSERVATIONAL
Enrollment
45
Participants
Timeline
Start Date
December 31, 2014
Primary Completion Date
March 31, 2015
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
DRUG
Sunitinib
Trial Locations (1)
35033
CHU de Rennes, Rennes
All Listed Sponsors
lead
Rennes University Hospital
OTHER
NCT02848768 - Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter